Kymera Therapeutics (KYMR) Revenue (2019 - 2025)
Historic Revenue for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $2.8 million.
- Kymera Therapeutics' Revenue fell 2611.6% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$238000.0, marking a year-over-year decrease of 10027.18%. This contributed to the annual value of $3.1 million for FY2024, which is 9605.56% down from last year.
- Per Kymera Therapeutics' latest filing, its Revenue stood at $2.8 million for Q3 2025, which was down 2611.6% from $11.5 million recorded in Q2 2025.
- Kymera Therapeutics' 5-year Revenue high stood at $47.9 million for Q4 2023, and its period low was -$36.6 million during Q4 2024.
- In the last 5 years, Kymera Therapeutics' Revenue had a median value of $11.5 million in 2022 and averaged $12.5 million.
- In the last 5 years, Kymera Therapeutics' Revenue skyrocketed by 46322.99% in 2021 and then crashed by 17638.72% in 2024.
- Quarter analysis of 5 years shows Kymera Therapeutics' Revenue stood at $15.3 million in 2021, then rose by 5.66% to $16.1 million in 2022, then soared by 196.7% to $47.9 million in 2023, then tumbled by 176.39% to -$36.6 million in 2024, then soared by 107.56% to $2.8 million in 2025.
- Its Revenue stands at $2.8 million for Q3 2025, versus $11.5 million for Q2 2025 and $22.1 million for Q1 2025.